Melanoma revenue contribution
In Bristol-Myers Squibb’s (BMY) third-quarter earnings conference call, the company estimated the contribution of melanoma indication to Opdivo’s US market revenues to be close to 30%. The contribution is ~20% in ex-US markets. The company expects the contribution of lung cancer indication to Opdivo’s revenues in ex-US markets to gradually decline as the drug penetrates deeper into other newly launched indications.
On December 20, 2017, Bristol-Myers Squibb issued a press release announcing FDA approval of Opdivo in adjuvant melanoma indication. According to Bristol-Myers Squibb’s Evercore ISI HealthCONx Conference transcript, the company has witnessed rapid adoption of the drug in the US market with rising patient treatment rates in the adjuvant melanoma setting. According to Bristol-Myers Squibb, the company accounts for 70% of the market share in adjuvant melanoma indication in the United States.
On July 31, Bristol-Myers Squibb issued a press release announcing European Commission approval of Opdivo in adjuvant melanoma indication. Opdivo was launched in Europe in adjuvant melanoma indication in September. The company is focused on securing reimbursement on a per market basis. According to the company’s third-quarter earnings conference call, the uptake of Opdivo for adjuvant melanoma in Germany is progressing at a rate similar to the rate witnessed in the United States and in line with Bristol-Myers Squibb’s expectations.
According to Bristol-Myers Squibb’s third-quarter earnings conference call, data from CheckMate-511 evaluating two safety profiles of different dosages of the Opdivo and Yervoy combination regimen in melanoma indication might provide physicians with higher optionality and flexibility while treating patients.
Next, we’ll discuss growth trends for Bristol-Myers Squibb in the renal cell carcinoma market.